^
TP53 mutation
CLL
BR
Resistant: B - Late Trials
ASH 2021 - 3 weeks
TP53 mutation
CLL
ICP-022
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr del(17p)
CLL
ICP-022
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr del(11q)
CLL
ICP-022
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
BTK C481
CLL
LOXO-305
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
SF3B1 mutation
CLL
obinutuzumab + GS-9973
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
NOTCH1 mutation
CLL
obinutuzumab + GS-9973
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
CLL
obinutuzumab + GS-9973
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
LGALS1 overexpression + LAG3 overexpression
CLL
ibrutinib
Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
LGALS1 overexpression + LAG3 overexpression
CLL
OTX-008
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
PTEN underexpression
CLL
ibrutinib
Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
miR-543 overexpression
CLL
ibrutinib
Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
miR-494 overexpression
CLL
ibrutinib
Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
miR-495 overexpression
CLL
ibrutinib
Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
TP53 mutation
CLL
BTK inhibitor
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr del(17p)
CLL
BTK inhibitor
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
LY9 expression
CLL
CAR-T immunotherapy
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
CD20 positive
CLL
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
ibrutinib + rituximab
Sensitive: A1 - Approval
Chr del(17p)
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
TP53 mutation
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
ICP-022
Sensitive: A1 - Approval
CD20 expression
CLL
rituximab-arrx
Sensitive: A1 - Approval
TP53 mutation
CLL
venetoclax
Sensitive: A1 - Approval
No biomarker
CLL
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
venetoclax + rituximab
Sensitive: A1 - Approval
Chr del(17p)
CLL
venetoclax
Sensitive: A1 - Approval
No biomarker
CLL
zanubrutinib
Sensitive: A1 - Approval
No biomarker
CLL
ibrutinib
Sensitive: A1 - Approval
No biomarker
CLL
ibrutinib + obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
rituximab
Sensitive: A1 - Approval
No biomarker
CLL
ofatumumab
Sensitive: A1 - Approval
CD20 positive
CLL
rituximab
Sensitive: A1 - Approval
No biomarker
CLL
venetoclax
Sensitive: A1 - Approval
No biomarker
CLL
rituximab/hyaluronidase
Sensitive: A1 - Approval
Chr del(17p)
CLL
ibrutinib
Sensitive: A1 - Approval
No biomarker
CLL
obinutuzumab + acalabrutinib
Sensitive: A1 - Approval
No biomarker
CLL
obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
acalabrutinib
Sensitive: A1 - Approval
Chr del(17p)
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
TP53 mutation
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
Chr del(17p)
CLL
acalabrutinib
Sensitive: A1 - Approval
TP53 mutation
CLL
acalabrutinib
Sensitive: A1 - Approval
No biomarker
CLL
alemtuzumab
Sensitive: A1 - Approval
TP53 mutation
CLL
idelalisib + ofatumumab
Sensitive: A1 - Approval
Chr del(17p)
CLL
idelalisib + ofatumumab
Sensitive: A1 - Approval
No biomarker
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
No biomarker
CLL
duvelisib
Sensitive: A1 - Approval
CD20 positive
CLL
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
bendamustine
Sensitive: A1 - Approval
No biomarker
CLL
bendamustine RTD
Sensitive: A1 - Approval
No biomarker
CLL
PCR
Sensitive: A2 - Guideline
Chr del(17p)
CLL
ofatumumab
Sensitive: A2 - Guideline
No biomarker
CLL
FCR
Sensitive: A2 - Guideline
TP53 mutation
CLL
rituximab + alemtuzumab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
rituximab
Sensitive: A2 - Guideline
TP53 mutation
CLL
venetoclax + rituximab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
venetoclax + rituximab
Sensitive: A2 - Guideline
TP53 mutation
CLL
zanubrutinib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
zanubrutinib
Sensitive: A2 - Guideline
No biomarker
CLL
rituximab + lenalidomide
Sensitive: A2 - Guideline
No biomarker
CLL
rituximab + idelalisib
Sensitive: A2 - Guideline
Chr del(11q)
CLL
ibrutinib
Sensitive: A2 - Guideline
Chr del(11q)
CLL
rituximab
Resistant: A2 - Guideline
TP53 mutation
CLL
ibrutinib
Sensitive: A2 - Guideline
TP53 mutation
CLL
ofatumumab
Resistant: A2 - Guideline
TP53 mutation
CLL
idelalisib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
idelalisib
Sensitive: A2 - Guideline
IGH mutation
CLL
ibrutinib
Sensitive: A2 - Guideline
IGH mutation
CLL
obinutuzumab
Sensitive: A2 - Guideline
IGH mutation
CLL
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
No biomarker
CLL
chlorambucil
Sensitive: A2 - Guideline
No biomarker
CLL
CD20 inhibitor + bendamustine
Sensitive: A2 - Guideline
TP53 mutation
CLL
lenalidomide
Sensitive: A2 - Guideline
TP53 mutation
CLL
rituximab + lenalidomide
Sensitive: A2 - Guideline
Chr del(17p)
CLL
lenalidomide
Sensitive: A2 - Guideline
Chr del(17p)
CLL
rituximab + lenalidomide
Sensitive: A2 - Guideline
No biomarker
CLL
lenalidomide
Sensitive: A2 - Guideline
TP53 deletion
CLL
idelalisib
Sensitive: A2 - Guideline
No biomarker
CLL
idelalisib
Sensitive: A2 - Guideline
No biomarker
CLL
rituximab + alemtuzumab
Sensitive: A2 - Guideline
TP53 deletion
CLL
ibrutinib
Sensitive: A2 - Guideline
TP53 deletion
CLL
rituximab
Sensitive: A2 - Guideline
TP53 mutation
CLL
rituximab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
alemtuzumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
alemtuzumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
pembrolizumab + nivolumab + ibrutinib
Sensitive: A2 - Guideline
BTK C481S
CLL
acalabrutinib
Resistant: A2 - Guideline
IGH mutation
CLL
FCR
Sensitive: A2 - Guideline
Chr del(17p)
CLL
pembrolizumab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
nivolumab
Sensitive: A2 - Guideline
Chr del(11q)
CLL
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
duvelisib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
obinutuzumab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
TP53 mutation
CLL
pembrolizumab + ibrutinib
Sensitive: A2 - Guideline
TP53 mutation
CLL
pembrolizumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
nivolumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
duvelisib
Sensitive: A2 - Guideline
TP53 mutation
CLL
obinutuzumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
rituximab + alemtuzumab
Sensitive: A2 - Guideline
No biomarker
CLL
OFAR
Sensitive: A2 - Guideline
No biomarker
CLL
R-CVAD
Sensitive: A2 - Guideline
No biomarker
CLL
EPOCH-R
Sensitive: A2 - Guideline